View More Recent Stories

Jun 1, 2025 07:14PM Kura Oncology (KURA) and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib
May 30, 2025 05:01AM Citizens JMP: Standard of Care Modifying Regimens at ASCO 2025
May 23, 2025 06:52AM Cantor Fitzgerald Reiterates Overweight Rating on Kura Oncology (KURA)
May 22, 2025 05:36PM Kura Oncology (KURA) and Kyowa Kirin announce abstract on ziftomenib trial
May 1, 2025 04:25PM Kura Oncology (KURA) Misses Q1 EPS by 4c
Apr 29, 2025 07:27AM H.C. Wainwright Reiterates Buy Rating on Kura Oncology (KURA)
Apr 29, 2025 04:20AM Citizens JMP Reiterates Market Outperform Rating on Kura Oncology (KURA)
Apr 9, 2025 05:10AM Citizens JMP Reiterates Market Outperform Rating on Kura Oncology (KURA)
Apr 8, 2025 07:30AM Kura Oncology (KURA) and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA
Mar 26, 2025 07:30AM Kura Oncology (KURA) Announces Preclinical Data for KO-2806
Feb 26, 2025 04:04PM Kura Oncology (KURA) Tops Q4 EPS by 35c
Feb 6, 2025 06:49AM BTIG Downgrades Kura Oncology (KURA) to Neutral
Feb 6, 2025 06:40AM Kura Oncology (KURA) PT Raised to $40 at H.C. Wainwright
Feb 5, 2025 04:03PM Kura Oncology (KURA) and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs
Feb 3, 2025 04:43AM JMP Securities Biotechnology Overview
Jan 6, 2025 04:30PM Kura Oncology (KURA) Announces Senior Executive Promotions
Dec 9, 2024 07:05AM Kura Oncology (KURA) and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting
Nov 22, 2024 01:33PM Kura Oncology (KURA) PT Lowered to $11 at Stifel
Nov 21, 2024 07:50AM TD Cowen Reiterates Buy Rating on Kura Oncology (KURA)
Nov 21, 2024 06:35AM Kura Oncology (KURA) PT Raised to $37 at H.C. Wainwright
Nov 21, 2024 05:38AM Kura Oncology (KURA) PT Lowered to $28 at Jefferies
Nov 20, 2024 05:00PM Kura Oncology (KURA) and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
Nov 18, 2024 07:32AM H.C. Wainwright Reiterates Buy Rating on Kura Oncology (KURA)
Nov 7, 2024 04:31PM Kura Oncology (KURA) Reports In-Line Q3 EPS
Nov 5, 2024 09:13AM Kura Oncology (KURA) to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting
Oct 25, 2024 08:05AM H.C. Wainwright Reiterates Buy Rating on Kura Oncology (KURA)
Oct 24, 2024 04:03AM UBS Starts Kura Oncology (KURA) at Buy
Oct 14, 2024 12:41AM Stifel Downgrades Kura Oncology (KURA) to Hold
Sep 17, 2024 07:30AM Kura Oncology (KURA) Appoints Michael Vasconcelles to its Board
Aug 8, 2024 04:45PM Kura Oncology (KURA) Tops Q2 EPS by 4c
Aug 8, 2024 07:30AM Kura Oncology (KURA) Announces FDA Clearance of IND Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors
Jun 25, 2024 06:44AM H.C. Wainwright Reiterates Buy Rating on Kura Oncology (KURA)
Jun 24, 2024 07:32AM Kura Oncology (KURA) Reports Preclinical Data Supporting Potential for Menin Inhibitor in Diabetes
Jun 18, 2024 08:45AM Treatment of Blood Cancers - Biopharma Companies Building out their Pipeline of Solutions
Mar 22, 2024 08:00PM 4 Buy-rated Healthcare stocks with 30-45% upside
View More Recent Stories